Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$31.5M | -$84.7M | -$192M | -$171M |
| Net income | -$29.8M | -$71.9M | -$178M | -$155M |
| EPS (diluted) | -$5.77 | -$1.99 | -$3.66 | -$2.29 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$29.2M | -$81.2M | -$166M | -$142M |
| Capital expenditures | — | $0.00 | $96.0K | $15.0K |
| Free cash flow | — | -$81.2M | -$166M | -$142M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $87.7M | $49.3M | $114M | $173M |
| Total assets | $114M | $252M | $206M | $662M |
| Shareholders' equity | -$52.3M | $241M | $191M | $647M |
| Retained earnings | -$52.8M | -$125M | -$303M | -$457M |
| Shares (wtd avg diluted) | 5.17M | 36.2M | 48.5M | 67.7M |
Every figure is extracted from Mineralys Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.